Physiological and pathological hypertrophy of the heart (WP1528)
Pathways in physiological and pathological hypertrophy of the heart. Largely based on the article from [https://www.ncbi.nlm.nih.gov/pubmed/11714087 Wang et al, 'Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach.] Hypertrohpy of the heart can be a physiological compensation for exercise, but it can also be a pathological compensation for hypertension and stress. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP1528 CPTAC Assay Portal]
How to Cite View full size Open in NDEx Download PDF Download PNG Download SVG Download GPML
last edited

Authors

Maartje Levels , Susan Coort , Alex Pico , Maintenance bot , Kristina Hanspers , Friederike Ehrhart , Egon Willighagen , Andika Tan , and Eric Weitz

Cited In

Organism

Homo sapiens

Communities

Diseases

Annotations

Cell Type Ontology: cardiac muscle cell

Disease Ontology: heart disease

Pathway Ontology: hypertrophic cardiomyopathy pathway

Participants

Label Type Compact Identifier
PE Metabolite hmdb:HMDB0002182
Calcium Metabolite hmdb:HMDB0000464
MKK3 GeneProduct ncbigene:5606
MYEF2 GeneProduct ncbigene:50804
MAPK14 GeneProduct ncbigene:1432
PRKCB GeneProduct ncbigene:5579
LIFR GeneProduct ncbigene:3977
JNK GeneProduct ncbigene:5599
CAMK2D GeneProduct ncbigene:817
CTF1 GeneProduct ncbigene:1489
JUN GeneProduct ncbigene:3725
PPP3CB GeneProduct ncbigene:5532
PKCE GeneProduct ncbigene:5581
RAC1 GeneProduct ncbigene:5879
EDN1 GeneProduct ncbigene:1906
FOS GeneProduct ncbigene:2353
MAPK11 GeneProduct ncbigene:5600
RHOA GeneProduct ncbigene:387
NFAT3 GeneProduct ncbigene:4776
JNK GeneProduct ncbigene:5599
PPP3CA GeneProduct ncbigene:5530
STAT3 GeneProduct ncbigene:6774
MAPK14 GeneProduct ncbigene:1432
GATA4 GeneProduct ncbigene:2626
MAPK1 GeneProduct ncbigene:5594
AGT GeneProduct ncbigene:183
IL6ST GeneProduct ncbigene:3572
CALM1 Protein ncbigene:801
Download TSV Drugst.One

References

  1. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, et al. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem. 1996 Apr 19;271(16):9535–45. PubMed Europe PMC Scholia
  2. Wollert KC, Chien KR. Cardiotrophin-1 and the role of gp130-dependent signaling pathways in cardiac growth and development. J Mol Med (Berl). 1997 Jul;75(7):492–501. PubMed Europe PMC Scholia
  3. Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem. 1998 Mar 6;273(10):5423–6. PubMed Europe PMC Scholia
  4. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998 Apr 17;93(2):215–28. PubMed Europe PMC Scholia
  5. Lim HW, Molkentin JD. Calcineurin and human heart failure. Nat Med. 1999 Mar;5(3):246–7. PubMed Europe PMC Scholia
  6. Olson EN, Molkentin JD. Prevention of cardiac hypertrophy by calcineurin inhibition: hope or hype? Circ Res. 1999 Apr 2;84(6):623–32. PubMed Europe PMC Scholia
  7. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999 Oct 21;341(17):1276–83. PubMed Europe PMC Scholia
  8. Jalili T, Takeishi Y, Walsh RA. Signal transduction during cardiac hypertrophy: the role of G alpha q, PLC beta I, and PKC. Cardiovasc Res. 1999 Oct;44(1):5–9. PubMed Europe PMC Scholia
  9. Clerk A, Sugden PH. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circ Res. 2000 May 26;86(10):1019–23. PubMed Europe PMC Scholia
  10. Takeishi Y, Ping P, Bolli R, Kirkpatrick DL, Hoit BD, Walsh RA. Transgenic overexpression of constitutively active protein kinase C epsilon causes concentric cardiac hypertrophy. Circ Res. 2000 Jun 23;86(12):1218–23. PubMed Europe PMC Scholia
  11. MacLellan WR. Advances in the molecular mechanisms of heart failure. Curr Opin Cardiol. 2000 May;15(3):128–35. PubMed Europe PMC Scholia
  12. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res. 2000 Oct 27;87(9):731–8. PubMed Europe PMC Scholia
  13. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000 Dec 1;19(23):6341–50. PubMed Europe PMC Scholia
  14. Wang Y. Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach. Curr Opin Pharmacol. 2001 Apr;1(2):134–40. PubMed Europe PMC Scholia
  15. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006 Aug;7(8):589–600. PubMed Europe PMC Scholia
Download TSV